When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. Daratumumab - Wikipedia

   en.wikipedia.org/wiki/Daratumumab

   Daratumumab, sold under the brand name Darzalex among others, is an anti-cancer monoclonal antibody medication. It binds to CD38 , [ 7 ] which is overexpressed in multiple myeloma cells. [ 8 ]

3. Daratumumab/hyaluronidase - Wikipedia

   en.wikipedia.org/wiki/Daratumumab/hyaluronidase

   It was approved for use in the United States in May 2020. [2] [7] [8]Efficacy of daratumumab and hyaluronidase-fihji (monotherapy) was evaluated in the COLUMBA trial (NCT03277105), an open-label non-inferiority trial randomizing 263 participants to daratumumab and hyaluronidase-fihj and 259 to intravenous daratumumab (daratumumab IV). [2]

4. Bortezomib/dexamethasone - Wikipedia

   en.wikipedia.org/wiki/Bortezomib/dexamethasone

   Bortezomib/dexamethasone is a combination drug against multiple myeloma. [1] When bortezomib is used by the trade name Velcade, the combination is called Vel/Dex (or Vel-Dex or Veldex ). Bortezomib is a proteasome inhibitor and dexamethasone is a corticosteroid .

5. GSK's Blood Cancer Drug Shows Improved Survival ... - AOL

   www.aol.com/finance/gsks-blood-cancer-drug-shows...

   The trial assessed Blenrep (belantamab mafodotin) in combination with bortezomib plus dexamethasone (BVd) versus Johnson & Johnson’s (NYSE:JNJ) Darzalex (daratumumab) in combination with ...

6. J&J Files sBLA for Darzalex in Expanded Myeloma Patient Group

   www.aol.com/news/j-j-files-sbla-darzalex...

   For premium support please call: 800-290-4726 more ways to reach us

7. Bortezomib - Wikipedia

   en.wikipedia.org/wiki/Bortezomib

   People received M (9 mg/m2 ) plus prednisone (60 mg/m2 ) daily for four days every 6 weeks or the same MP schedule with bortezomib, 1.3 mg/m2 iv on days 1, 8, 11, 22, 25, 29, and 32 of every 6 week cycle for 4 cycles then once weekly for 4 weeks for 5 cycles. [24] Time- to- progression (TTP) was the primary efficacy endpoint. [24]